Detergent resistant membrane-associated IDE in brain tissue and cultured cells: Relevance to A and insulin degradation

Molecular Neurodegeneration

Volumn 3, Issue 1, 2008, Pages

  Bulloj, Ayelén ^a   Leal, María C ^a   Surace, Ezequiel I ^a   Zhang, Xue ^b   Xu, Huaxi ^b   Ledesma, Maria D ^c   Castaño, Eduardo M ^a   Morelli, Laura ^a  

^a FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^b BURNHAM INSTITUTE   (United States)

^c CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CHOLESTEROL; FLOTILLIN 1; INSULIN; INSULIN RECEPTOR; INSULINASE; METALLOPROTEINASE; METHYL BETA CYCLODEXTRIN; TUBULIN;

ALLELE; ANIMAL CELL; ARTICLE; BRAIN TISSUE; CELLULAR DISTRIBUTION; CLEARANCE; CONTROLLED STUDY; CYTOSOL; DETERGENT RESISTANT MEMBRANE; ENZYME ACTIVITY; ENZYME LOCALIZATION; EXTRACELLULAR SPACE; FRACTIONATION; GENE DELETION; HALF LIFE TIME; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; HYDROPHOBICITY; IMMUNOFLUORESCENCE; IMMUNOGOLD ELECTRON MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEGRADATION; LIPID COMPOSITION; MEMBRANE; MOUSE; NONHUMAN; PROTEIN DEGRADATION;

MUS;

EID: 61849129656     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-3-22     Document Type: Article

References (56)

1. Insulin-degrading enzyme: embarking on amyloid destruction. IV Kurochkin, Trends Biochem Sci 2001 26 421 425 11440853
2. Amyloid degradation: a challenging task for brain peptidases. L Morelli A Bulloj MC Leal EM Castão, Subcell Biochem 2005 38 129 145 15709476
3. Insulin degradation: mechanisms, products, and significance. WC Duckworth, Endocr Rev 1988 9 319 345 3061785
4. Insulin degradation: progress and potential. WC Duckworth RG Bennett FG Hamel, Endocr Rev 1998 19 608 624 9793760
5. Inducible expression and cellular localization of insulin-degrading enzyme in a stably transfected cell line. WL Kuo BD Gehm MR Rosner W Li G Keller, J Biol Chem 1994 269 22599 22606 8077210
6. Insulin degrading enzyme is localized predominantly at the cell surface of polarized and unpolarized human cerebrovascular endothelial cell cultures. JA Lynch AM George PB Eisenhauer K Conn W Gao I Carreras JM Wells A McKee MD Ullman RE Fine, J Neurosci Res 2006 83 1262 1270 16511862
7. Neurons regulate extracellular levels of amyloid -protein via proteolysis by insulin-degrading enzyme. K Vekrellis Z Ye WQ Qiu D Walsh D Hartley V Chesneau MR Rosner DJ Selkoe, J Neurosci 2000 20 1657 1665 10684867
8. Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration. AJ Turner L Fisk NN Nalivaeva, Ann N Y Acad Sci 2004 1035 1 20 15681797
9. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid -protein. W Farris S Mansourian MA Leissring EA Eckman L Bertram CB Eckman RE Tanzi DJ Selkoe, Am J Pathol 2004 164 1425 1434 15039230
10. Insulin-degrading enzyme regulates the levels of insulin, amyloid -protein, and the -amyloid precursor protein intracellular domain in vivo. W Farris S Mansourian Y Chang L Lindsley EA Eckman MP Frosch CB Eckman RE Tanzi DJ Selkoe S Guenette, Proc Natl Acad Sci USA 2003 100 4162 4167 12634421
11. Enhanced proteolysis of -amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. MA Leissring W Farris AY Chang DM Walsh X Wu X Sun MP Frosch DJ Selkoe, Neuron 2003 40 1087 1093 14687544
12. Dynamic association of human insulin receptor with lipid rafts in cells lacking caveolae. S Vainio S Heino JE Mansson P Fredman E Kuismanen O Vaarala E Ikonen, EMBO Rep 2002 3 95 100 11751579
13. HPLC analysis of insulin degradation products from isolated hepatocytes. Effects of inhibitors suggest intracellular and extracellular pathways. FG Hamel DE Peavy MP Ryan WC Duckworth, Diabetes 1987 36 702 708 3552802
14. 125I]-insulin metabolism by the rat liver in vivo: evidence that a neutral thiol-protease mediates rapid intracellular insulin degradation. FG Williams DE Johnson GE Bauer, Metabolism 1990 39 231 241 2407925
15. Insulin degrading enzyme is capable of degrading receptor-bound insulin. K Yonezawa K Yokono K Shii, Biochem Biophys Res Commun 1998 150 2 605 614
16. Insulin-degrading enzyme in brain microvessels: proteolysis of amyloid vasculotropic variants and reduced activity in cerebral amyloid angiopathy. L Morelli RE Llovera I Imathov L Lue B Frangione J Ghiso EM Castão, J Biol Chem 2004 279 56004 56013 15489232
17. Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology. MC Leal VB Dorfman AF Gamba B Frangione T Wisniewski EM Castão EM Sigurdsson L Morelli, J Neuropathol Exp Neurol 2006 65 976 987 17021402
18. Metabolism of the "Swedish" amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the " -secretase" site occurs in the golgi apparatus. G Thinakaran DB Teplow R Siman B Greenberg SS Sisodia, J Biol Chem 1996 271 9390 9397 8621605
19. Presenilin 1 Met146Leu variant due to an A -> T transversion in an early-onset familial Alzheimer's disease pedigree from Argentina. L Morelli MI Prat E Levy CA Mangone EM Castão, Clin Genet 1998 53 469 473 9712537
20. Generation of viable cholesterol-free mice. A Wechsler A Brafman M Shafir M Heverin H Gottlieb G Damari S Gozlan-Kelner I Spivak O Moshkin E Fridman Y Becker R Skaliter P Einat A Faerman I Bjorkhem E Feinstein, Science 2003 302 2087 14684813
21. Identification of a third Protein 4.1 tumor suppressor, protein 4.1R, in meningioma pathogenesis. VA Robb W Li P Gascard A Perry N Mohandas DH Gutmann, Neurobiol Dis 2003 13 191 202 12901833
22. Raft disorganization lads to reduced plasmin activity in Alzheimer's disease brains. MD Ledesma J Abad-Rodriguez C Galvan E Biondi P Navarro A Delacourte C Dingwal CG Dotti, EMBO Rep 2003 4 1190 1196 14618158
23. A new color reaction for the quantitacion of serum cholesterol. RL Searcy LM Bergquist, Clin Chim Acta 1960 5 192 199 14444356
24. Degadation of soluble amyloid -peptides 1 40, 142, and the Dutch variant 140Q by insulin degrading enzyme from Alzheimer disease and control brains. A Perez L Morelli JC Cresto EM Castão, Neurochem Res 2000 25 247 255 10786709
25. Characterization of detergent-insoluble complexes containing the familial Alzheimer's disease-associated presenilins. ET Parkin I Hussain EH Karran AJ Turner NM Hooper, J Neurochem 1999 72 1534 1543 10098859
26. Overexpression of insulin degrading enzyme: cellular localization and effects on insulin signaling. KA Seta RA Roth, Biochem Biophys Res Commun 1997 231 167 171 9070242
27. Analysis of raft affinity of membrane proteins by detergent-insolubility. DA Brown, Methods Mol Biol 2007 398 9 20 18214370
28. Detergent resistance as a tool in membrane research. D Lingwood K Simons, Nat Protoc 2007 2 2159 2165 17853872
29. Dimeric amyloid protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. T Kawarabayashi M Shoji LH Younkin L Wen-Lang DW Dickson T Murakami E Matsubara K Abe KH Ashe SG Younkin, J Neurosci 2004 24 3801 3809 15084661
30. Dynamics of membrane lipid domains in neuronal cells differentiated in culture. E Ottico A Prinetti S Prioni C Giannotta L Basso V Chigorno S Sonnino, J Lipid Res 2003 44 2142 2151 12897192
31. The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. A Crameri E Biondi K Kuehnle D Lütjohann KM Thelen S Perga CG Dotti RM Nitsch MD Ledesma MH Mohajeri, EMBO J 25 432 443 16407971
32. The sorbin homology domain: a motif for the targeting of proteins to lipid rafts. A Kimura CA Baumann SH Chiang AR Saltiel, Proc Natl Acad Sci USA 2001 98 9098 9103 11481476
33. Tyrosine phosphorylation of adaptor protein 3BP2 induces T cell receptor-mediated activation of transcription factor. X Qu K Kawauchi-Kamata SM Miah T Hatani H Yamamura K Sada, Biochemistry 2005 44 3891 3898 15751964
34. Hsc70 and Hsp70 interact with phosphatidylserine on the surface of PC12 cells resulting in a decrease of viability. N Arispe M Doh O Simakova B Kurganov A De Maio, FASEB J 2004 18 1636 1645 15522909
35. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Y Shen A Joachimiak MR Rosner WJ Tang, Nature 2006 443 870 874 17051221
36. Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread. Q Li MA Ali JI Cohen, Cell 2006 127 305 316 17055432
37. Association of insulin-degrading enzyme with a 70 kDa cytosolic protein in hepatoma cells. F Authier PH Cameron V Taupin, Biochem J 1996 319 149 158 8870662
38. On the mechanism of ligand-induced down-regulation of insulin receptor level in the liver cell. M Krupp MD Lane, J Biol Chem 1981 256 1689 1694 7007369
39. Lipid rafts mediate the synaptic localization of alpha-synuclein. DL Fortin MD Troyer K Nakamura S Kubo MD Anthony RH Edwards, J Neurosci 2004 24 6715 6723 15282274
40. Sphingolipid-enriched membrane domains from rat cerebellar granule cells differentiated in culture. A compositional study. A Prinetti V Chigorno G Tettamanti S Sonnino, J Biol Chem 2000 275 11658 11665 10766784
41. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. M Simons P Keller B De Strooper K Beyreuther CG Dotti K Simons, Proc Natl Acad Sci U S A 1998 95 11 6460 6464 9600988
42. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Abad-Rodriguez MD Ledesma K Craessaerts S Perga M Medina A Delacourte C Dingwall B De Strooper CG Dotti, J Cell Biol 2004 167 953 960 15583033
43. Low Cholesterol stimulates the nonamyloidogenic pathway by its effect on the -secretase ADAM 10. E Koiro G Gimpl S Lammich W Marz F Fahrenholz, Proc Natl Acad Sci USA 2001 98 5815 5820 11309494
44. Simvastatin strongly reduces levels of Alzheimer's disease -amyloid peptide A42 and A40 in vitro and in vivo. K Fassbender M Simons C Bergmann M Stroick D Lutjohann P Keller H Runz S Kuhl T Bertsch K Von Bergmann M Hennerici K Beyreuther T Hartmann, Proc Natl Acad Sci USA 2001 98 5856 5861 11296263
45. -secretase activity is present in Rafts but is not cholesterol-dependent. S Wada M Morishima-Kawashima Y Qi H Misono Y Shimuda Y Ohno-Iwashita Y Ihara, Biochemistry 2003 42 13977 13986 14636066
46. Dynamics of membrane lipid domains in neuronal cells differentiated in culture. E Ottico A Prinetti S Prioni C Giannotta L Basso V Chigorno S Sonnino, J Lipid Res 2003 44 2142 2151 12897192
47. Increased production of matrix metalloproteinases in enriched astrocytes and mixed hippocampal cultures treated with -amyloid peptides. S Deb PE Gottshall, J Neurochem 1996 66 1641 1647 8627321
48. Cholesterol depletion disrupts caveolae and insulin receptor signalling form metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control. S Parpal M Karlsson H Thorn P Stralfors, J Biol Chem 2001 276 9670 9678 11121405
49. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. M Molander-Melin K Blennow N Bogdanovic B Dellheden JE Mansson P Fredman, J Neurochem 2005 92 171 182 15606906
50. The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. I Greeve I Hermans-Borgmeyer C Brellinger D Kasper T Gomez-Isla C Behl B Levkau RM Nitsch, J Neurosci 2000 20 7345 7352 11007892
51. Gangliosides in cerebrospinal fluid in 'probable Alzheimer's disease. K Blennow P Davidson A Wallin P Fredman CG Gottfries JE Mansson L Svennerholm, Arch Neurol 1991 48 1032 1035 1929894
52. Cholesterol, lipid rafts, and disease. K Simons R Ehehalt, J Clin Invest 2002 110 597 603 12208858
53. Insulin Resistance as a Membrane Microdomain Disorder. J Inokuchi, YAKUGAKU ZASSHI 2007 127 579 586 17409686
54. Insulin increases CSF Abeta42 levels in normal older adults. GS Watson ER Peskind S Asthana K Purganan C Wait D Chapman MW Schwartz S Plymate S Craft, Neurology 2003 60 1899 1903 12821730
55. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer disease. SM de la Monte M Tong N Lester-Coll M Plater Jr JR Wands, J Alzheimers Dis 2006 10 1 89 109 16988486
56. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. S Craft, Neurobiol Aging 2005 26 Suppl 1 65 69 16266773